key: cord-0693823-4ddyjhl6
authors: Comune, Chiara; Laezza, Maria Paola; Giunta, Piera; D’Andrea, Luca; Cennamo, Gilda
title: Management of anti-VEGF intravitreal treatment at University Hospital Federico II of Naples during COVID-19 pandemic lockdown
date: 2020-10-16
journal: Ther Adv Ophthalmol
DOI: 10.1177/2515841420966861
sha: ed3021a2832fcad4e02d33a0aece6674d43e251c
doc_id: 693823
cord_uid: 4ddyjhl6

nan

exposing them to the risk of infection. We investigated through telephonic consultation and on the day of the visit about fever, symptoms of respiratory tract infection, recent travel history, occupation, contact with individuals affected by COVID-19, and presence of certain symptoms in the family. We recommended patients to enter the clinic without accompanying adults, if possible. It was also advised to postpone appointments for at least 14 days for individuals suspected of having COVID-19 and to regard patients with conjunctivitis as contagious carriers. Beyond the usual scrupulous cleaning procedures, new sanitization measures have been adopted.

Ophthalmologists always wore at least FFP2 mask and safety goggles or face shield during examination and gloves were changed before examining each patient. Shields acting as a barrier between the patient and physician were placed on biomicroscopes and were disinfected between examinations. All patients were advised to wear a surgical face mask, adhere to the appointment timings, and avoid gatherings in the waiting room. A structural reorganization of the waiting room, the ambulatory, and the theater was carried out. The waiting room was placed in a large and ventilated space; we reduced the number of seats, spaced the remaining ones, and marked those that can be occupied. We organized scheduled appointments at settled times to avoid overlapping visits and crowds in the waiting room. We positioned a hydroalcoholic sanitizing dispenser at the entrance and in the workplace for sanitizing hands. We placed signs explaining the procedures to be followed for the prevention of the risk of contagion at the entrance of the ambulatory. A total of 90 eyes from 89 different patients (48 women, 41 men, mean age: 67.46 ± 14.21 Letter to the Editor Therapeutic Advances in Ophthalmology 12 2 journals.sagepub.com/home/oed years) were treated using anti-VEGF IVI between 9 March 2020 and 4 May 2020 at the Eye Clinic of the University of Naples 'Federico II'. Fiftyone patients were affected by neovascular AMD, 14 by RVO, 9 by DME, and 9 by PDR, of which 1 was complicated by neovascular glaucoma, 1 developed hemovitreous, and 7 developed myopic CNV. Patients were selected based on pathology (monocular, stage of disease), vision acuity, age, comorbidities, and previous response to IVI. We gave priority based on pathology in the following order: neovascular AMD, myopic CNV, PDR, ischemic RVO, and DME. We postponed anti-VEGF IVI for patients with DME and branch retinal occlusion because they are less likely to suffer from irreversible vision loss in the short term, except for naïve patients with recent significant vision loss. 6 We preferred deferring patients aged 80 years or older and affected by other pathologies, especially respiratory and oncologic ones. Monocular patients, those with bilateral disease, or those with high risk of vision loss in the short term were prioritized. We did not switch any treatment regimen. We enrolled five patients for every IVI session. One patient, despite a negative telephone triage, had a high body temperature on the day of IVI, so the treatment was postponed and he was treated 30 days after complete recovery. Moreover, among the 89 patients, 85 were already under fixed dosing treatment regimen at our facility, while 4 were enrolled during the quarantine period (treatment-naïve). These four patients came to our observation as an emergency visit because of vision loss. We diagnosed neovascular AMD in these four naïve patients using multimodal imaging, spectral-domain optical coherence tomography (SD-OCT), and OCT angiography (OCTA) with Spectralis Heidelberg Retina Angiograph (HRA)-OCT (Heidelberg Engineering, Germany). The lack of support from anesthesiologists, engaged in COVID departments, prevented from performing traditional fluorescein and indocyanine green angiography. OCTA is a rapid, noninvasive, repeatable new modality to visualize the microvasculature of the retina and optic disk without dye injection 7 and represented the best modality to check patients in this circumstance. According to the international guidelines, 8, 9 before injection, a 5% povidone-iodine solution was applied to periocular, palpebral skin and the conjunctival sac for at least 30 s. Following injection, an antibiotic ointment was applied to all patients. The choice of the antibiotic was determined by community resistance profiles and the patient's allergies. The postinjection therapy consisted of topical combination of antibiotic and corticosteroid drops three times a day for 3 days to prevent ocular infections. Because of the relatively low risk of adverse events associated with IVI, 9 we decided to avoid the usual follow-up after 48 h, but an emergency contact number was provided to our patients in case of any complications. No ocular complications were detected in all patients after telephonic consultation. In conclusion, we ensured anti-VEGF therapeutic continuity prioritizing treatment for patients with high risk of irreversible vision loss. Naïve treatments were enrolled using a noninvasive OCTA device for containing the infection risk for patients and health care staff and providing the best possible care to our patients.

A new coronavirus associated with human respiratory disease in China

No time for tears

Aerosol and surface stability of SARSCoV-2 as compared with SARS-CoV-1

Conjunctivitis and COVID-19: a meta-analysis

Epub ahead of print 24

Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection

Persistent macular thickening following intravitreous aflibercept

ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial

Optical coherence tomography angiography: review of current technical aspects and applications in chorioretinal disease

Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic

Intravitreal injection technique and monitoring: updated guidelines of an expert panel

Visit SAGE journals online journals.sagepub.com/ home/oed

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

The authors received no financial support for the research, authorship, and/or publication of this article.

Chiara Comune https://orcid.org/0000-0002-8245-8837